Therefore, the primary aim of this study was to ascertain whether a supervised exercise training program lasting 3 months would reduce trastuzumab-induced cardiotoxicity (TIC) in HER2-positive breast cancer undergoing adjuvant trastuzumab. The gene discussed is ERBB2; the disease is breast cancer.